Jens Hillengass, MD

Trials

Studies that name Jens Hillengass, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:21 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT06627751 · Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

  Roswell Park Cancer Institute · recruiting · Extramedullary Disease in Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma · principal investigator
• Ph1
  NCT06622005 · SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

  Roswell Park Cancer Institute · recruiting · Recurrent Multiple Myeloma, Refractory Multiple Myeloma · principal investigator
• Ph2
  NCT03457142 · Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

  Roswell Park Cancer Institute · terminated · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma · principal investigator
• Ph1
  NCT02334865 · SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

  Roswell Park Cancer Institute · active not recruiting · Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 13:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.